高萌科技(08065.HK)註銷920萬份及授出980萬份購股權
格隆匯1月2日丨高萌科技(08065.HK)宣佈,有關向承授人授出920萬份股購股權。於公告日期,概無承授人自授出購股權以來行使該等購股權。經公司董事會批准及所有承授人的同意,上述合共920萬份購股權已根據購股權計劃之條款註銷,自2020年1月2日起生效。
公司宣佈,於2020年1月2日,公司根據於2017年9月20日採納的購股權計劃,向承授人授出980萬份購股權,以供認購公司普通股,每股行使價0.259港元,較1月2日收市價0.25港元溢價3.60%,有效期為5年。
其中,公司行政總裁陳澤麟獲授200萬股,公司附屬高明科技工程有限公司的董事衞杏英獲授70萬股及公司祕書胡劭卉獲授30萬股。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.